Harmony Biosciences Holdings, Inc.HRMYNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 85% recommend buying.

Consensus Rating

Buy

13 analysts·Moderate coverage

85%

Rating Distribution

Strong Buy

00%

Buy

1185%

Hold

00%

Sell

215%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 33% higher.

Bear Case

$43.00

+14%

Consensus

$50.20

+33%

Bull Case

$62.00

+64%

Price Range13 analysts

Low

Consensus

High

$43.00

$62.00

Current Target

Current Price

$37.84

Upside to Target

$12.36

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$4.05(7 analysts)

P/E12x

Current: 11.9x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+12.81%

EPS+16.31%

FY2028

Rev+16.58%

EPS+29.33%

FY2029

Rev+7.71%

EPS+17.97%

Earnings Surprises

Beat rate:67%(8/12 quarters)

Avg surprise:+44.6%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 8, 2026Truist Financial

Harmony Biosciences price target lowered to $45 from $48 at Truist

Target:$45.00

+19.8%from $37.55

Dec 1, 2025Mizuho Securities

Harmony Biosciences price target raised to $46 from $39 at Mizuho

Target:$46.00

+30.3%from $35.29

Nov 24, 2025Oppenheimer

Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY) Post Mgmt Meet

Target:$62.00

+80.7%from $34.31

Oct 29, 2025Mizuho Securities

Harmony Biosciences price target raised to $36 from $35 at Mizuho

Target:$36.00

+21.5%from $29.64

Oct 15, 2025UBS

Harmony Biosciences price target lowered to $43 from $50 at UBS

Target:$43.00

+60.2%from $26.84

Sep 25, 2025H.C. Wainwright

Harmony Biosciences price target lowered to $55 from $70 at H.C. Wainwright

Target:$55.00

+103.4%from $27.04

Jul 10, 2025Goldman Sachs

Harmony Biosciences resumed with a Neutral at Goldman Sachs

Target:$33.00

-3.9%from $34.33

Apr 28, 2025UBS

Harmony Biosciences price target lowered to $48 from $55 at UBS

Target:$48.00

+63.5%from $29.36

Oct 30, 2024Goldman Sachs

Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY)

Target:$28.00

-32.5%from $41.49

Oct 10, 2024Mizuho Securities

Harmony Biosciences price target raised to $52 from $42 at Mizuho

Target:$52.00

+54.8%from $33.60

Sep 10, 2024UBS

UBS starts Harmony Biosciences with Buy on Wakix growth

Target:$56.00

+51.8%from $36.89

Aug 8, 2024Mizuho Securities

Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $42 at Mizuho

Target:$42.00

+25.2%from $33.55

Jun 24, 2024Oppenheimer

Oppenheimer on Harmony Biosciences Holdings Inc. (HRMY): 'WAKIX Approved for EDS in Pediatric Narcolepsy, Small But Meaningful Commercial Opportunity'

Target:$56.00

+84.3%from $30.39

May 1, 2024Needham

Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $52 at Needham

Target:$52.00

+71.2%from $30.37

Apr 30, 2024Raymond James

Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $37 at Raymond James

Target:$37.00

+19.7%from $30.91

Oct 14, 2022Jefferies

Harmony Biosciences upgraded to Buy from Hold at Jefferies

Target:$61.00

+28.1%from $47.63

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance